Clinical trial
Effects of Andriol Testocaps in Symptomatic Late-Onset Hypogonadism (43203)
NCT00434824 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00434824 |
|---|---|
| Title | Effects of Andriol Testocaps in Symptomatic Late-Onset Hypogonadism (43203) |
| Official title | A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Oral Administration of Different Doses of Org 538 in Symptomatic Aging Men With Androgen Deficiency |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hypogonadism, Androgens |
| Intervention type | Drug |
| Interventions | Oral testosterone undecanoate (Andriol), Placebo |
| Enrollment | 322 |
| Start date | Nov 1, 2001 |
| Primary completion | Jul 1, 2004 |
| Completion | Jul 1, 2004 |
| First posted | Feb 13, 2007 |
| Last update posted | Apr 16, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: